

FIGHTING ANTIMICROBIAL RESISTANCE, CURZA ANNOUNCES \$5M IN FINANCING

Proceeds to Fund Development of Novel Antibiotics to Treat Antibiotic Resistant Infections

SALT LAKE CITY, Utah—November 14, 2015—Curza, a privately-held small-molecule drug development company, announced that they raised \$5 million in seed financing. These funds come from Clarke Capital Partners and other strategic high net worth individuals.

Proceeds will be used to continue development of Curza's quickly progressing novel antibiotic and oncology programs. This news will be welcomed by the medical community, as several organizations are urgently calling for the introduction of new antibiotics to treat infections. As antibiotics have been used, strains of bacteria have adapted to make current therapies ineffective. According to the World Health director general Dr. Margaret Chan, without products to replace current antibiotics, "the world is heading to a post-antibiotic era in which common infections, especially those caused by gram-negative bacteria, will once again kill."

Ryan Davies, CEO of Curza, commented in an interview that "part of the problem is that the majority of drugs that have been developed over the past several decades have been derivatives or analogs of old antibiotics." Because only a limited number of analogs can be created from each core, antibiotic resistance is quickly catching up to antibiotic technology. Curza's new class will extend humanity's ability to fight deadly pathogens.

Curza appreciates the support from new and existing investors. The \$5M in seed financing will prove essential in developing Curza's life-saving technology and is a critical step in the battle against antimicrobial resistance.

About Curza—Curza is a Utah-based drug development company focused on developing novel therapeutics to combat antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and is backed by Clarke Capital Partners and other private investors. Visit www.curza.com for more information.

For media inquiries, please contact: Ryan Davies at rd@curza.com